글로벌 1차 Clostridioides Difficile 감염 시장 – 2029년까지의 산업 동향 및 예측

1차 Clostridioides Difficile 감염 시장 분석 및 규모

글로벌 1차 클로스트리디움 디피실 감염 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 클로스트리디움 디피실 감염은 최근 몇 년 동안 많은 새로운 균주가 등장하고 항균제 내성이 증가함에 따라 상당히 증가했습니다. 이는 항생제 관련 설사의 밀접한 관련 원인 중 하나로, 가성막성 대장염, 경미하고 자가 제한적인 설사에서 심각한 설사, 생명을 위협하는 급성 대장염과 같은 증상이 나타나며, 이는 일반적으로 사망에 이릅니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

 Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 1차 클로스트리디오이드 디피실 감염 시장의 성장률을 분석합니다. 글로벌 1차 클로스트리디오이드 디피실 감염 시장의 예상 CAGR은 언급된 예측 기간 동안 약 6.30%인 경향이 있습니다. 이 시장은 2021년에 10억 달러로 평가되었으며 2029년까지 16억 3천만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

일차성 클로스트리디움 디피실은 설사에서 생명을 위협하는 대장 염증에 이르기까지 다양한 증상을 유발할 수 있는 세균성 감염입니다. 또한 지역사회 관련 설사의 원인으로 발전하여 지역사회 관련 감염의 유병률이 증가했습니다. 임상적 질병은 경미한 설사에서 급성 대장염 및 사망에 이르기까지 심각도가 다양합니다.

1차 Clostridioides Difficile 감염 시장 범위 및 세분화

Global Primary Clostridioides Difficile Infection Market Dynamics

Drivers

• Rising Adoption of Antibiotics

Clostridium difficile infection is primarily associated with long-term antibiotic use. Increased antibiotic consumption changes the colon bacteria, allowing Clostridium difficile bacteria to grow. Antibiotics such as cephalosporins, clindamycin, and quinolones are more likely to cause Clostridium difficile infection (CDI). The higher use of these antibiotics is increasing the prevalence of clostridium difficile infection, which is most likely to boost the demand for its treatments. Therefore, the increasing consumption of antibiotics acts as a major driver of growth in the global primary clostridium difficile infection treatment market.

• Growing Collaborations of Public-Private Organizations

With numerous small innovative players who are functioning in the market, there are several high-growth opportunities for major stakeholders to buy out companies so as to understand microbiomes with the aim of identifying new drugs and drug targets for multiple indications, such as liver disorders, diabetes, obesity, and metabolic disorders. Many market players are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized R&D techniques. Major companies have had numerous collaborations and partnerships in the last two years. Thus, all these partnerships are boosting the growth of the market.

Opportunities

• Rising Drug Development Activities

Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth in the market by providing doctors with an alternate treatment option. Additionally, the development of a new class of non-antibiotic drugs and vaccines is most likely to open up a large number of opportunities for major market players while also increasing the competition for manufacturing better treatment options. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth in the near future.

• Increasing Demand for Retail Pharmacies

The rise in the number of these infections therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could limit the growth of the global primary clostridioides difficile infection market during a forecast period.

• High Cost For Drug Development

The current treatment options that are available for CDIs are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. The development of a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.  

This global primary clostridioides difficile infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global primary clostridioides difficile infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Primary Clostridioides Difficile Infection Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. Although, with the relaxation of government restrictions associated with the pandemic and the occurrence of virtual clinical trials, R&D activities started their recovery since 2021.

Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting towards normal patients again. Thus, this will significantly impact the global primary clostridioides difficile infection market.

Global Primary Clostridioides Difficile Infection Market Scope

The global primary clostridioides difficile infection market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Surgery
• Others

Route of Administration

• Oral
• Injectable
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Primary Clostridioides Difficile Infection Market Regional Analysis/Insights

The global primary clostridioides difficile infection market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global primary clostridioides difficile infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global primary clostridioides difficile infection market throughout the forecasted period due to the presence of key manufacture of the product and increased prevalence of clostridioides difficile infection in this region.  

Asia-Pacific dominates the market due to increased prevalence of clostridioides difficile infection and increasing population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Primary Clostridioides Difficile Infection Market Share Analysis

글로벌 1차 클로스트리디오이데스 디피실 감염 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 글로벌 1차 클로스트리디오이데스 디피실 감염 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 1차 클로스트리디움 디피실 감염 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 아스트라제네카(영국)
• 릴리(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 머크앤코(미국)
• 파이저 주식회사(미국)
• GSK plc (영국)
• 히크마 제약(영국)
• Cipla Inc. (인도)
• STI Pharma, LLC(미국)

SKU-54393